Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Duarte, L. Clavería, J. Pedro-Cuesta, J. Pedro-Cuesta, A. Sempere, F. Coria, D. Calne (1995)
Screening Parkinson's disease: A validated questionnaire of high specificity and sensitivityMovement Disorders, 10
K. Black, A. Snyder, J. Koller, M. Gado, J. Perlmutter (2001)
Template Images for Nonhuman Primate Neuroimaging: 1. BaboonNeuroImage, 14
K. Black, J. Koller, A. Snyder, J. Perlmutter (2001)
Template Images for Nonhuman Primate Neuroimaging: 2. MacaqueNeuroImage, 14
M. Folstein, M. Folstein, S. Folstein, S. Folstein, P. McHugh, P. McHugh (1975)
“Mini-mental state”: A practical method for grading the cognitive state of patients for the clinicianJournal of Psychiatric Research, 12
V. Bonifati, P. Rizzu, M. Baren, O. Schaap, G. Breedveld, E. Krieger, M. Dekker, F. Squitieri, P. Ibáñez, M. Joosse, J. Dongen, N. Vanacore, J. Swieten, A. Brice, G. Meco, C. Duijn, B. Oostra, P. Heutink (2002)
Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset ParkinsonismScience, 299
O. Rascol, D. Brooks, A. Korczyn, D. Pp, C. Clarke, A. Lang (2000)
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.The New England journal of medicine, 342 20
M. Polymeropoulos, C. Lavedan, E. Leroy, S. Ide, A. Dehejia, A. Dutra, B. Pike, H. Root, J. Rubenstein, R. Boyer, E. Stenroos, S. Chandrasekharappa, A. Athanassiadou, T. Papapetropoulos, W. Johnson, A. Lazzarini, R. Duvoisin, G. Iorio, L. Golbe, R. Nussbaum (1997)
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.Science, 276 5321
A. Whone, R. Watts, A. Stoessl, Margaret Davis, S. Reske, C. Nahmias, A. Lang, O. Rascol, M. Ribeiro, P. Remy, W. Poewe, R. Hauser, D. Brooks (2003)
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET studyAnnals of Neurology, 54
E. Leroy, R. Boyer, G. Auburger, B. Leube, G. Ulm, É. Mezey, G. Harta, M. Brownstein, Sobhanadditya Jonnalagada, Tanya Chernova, A. Dehejia, C. Lavedan, T. Gasser, P. Steinbach, K. Wilkinson, M. Polymeropoulos (1998)
The ubiquitin pathway in Parkinson's diseaseNature, 395
G. Chan, J. Holden, A. Stoessl, A. Samii, D. Doudet, T. Dobko, K. Morrison, M. Adam, M. Schulzer, D. Calne, T. Ruth (1999)
Reproducibility studies with 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 40 2
K. Marek, R. Innis, C. Dyck, B. Fussell, M. Early, S. Eberly, D. Oakes, J. Seibyl (2001)
[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression.Neurology, 57 11
W. Heiss, R. Hilker (2004)
The sensitivity of 18‐fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's diseaseEuropean Journal of Neurology, 11
C. Lee, A. Samii, V. Sossi, T. Ruth, M. Schulzer, J. Holden, J. Wudel, P. Pal, R. Fuente-Fernández, D. Calne, A. Stoessl (2000)
In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's diseaseAnnals of Neurology, 47
B. Ravina, A. Siderowf, J. Farrar, H. Hurtig (2001)
Welding-related parkinsonism: clinical features, treatment, and pathophysiology.Neurology, 57 5
(1993)
Synthesis of [ 11 C ] methoxy derivative of a - dihydrotetrabenazine for PET imaging of monoaminergic nerve terminals
R. Holloway, I. Shoulson, K. Kieburtz, M. Mcdermott, P. Tariot, Cornelia Kamp, D. Day, A. Shinaman, S. Fahn, A. Lang, K. Marek, J. Seibyl, W. Weiner, M. Welsh, R. Pahwa, S. Coe, L. Barclay, L. Sutherland, K. Hildebrand, J. Hubble, C. Weeks, P. LeWitt, J. Miyasaki, J. Duff, E. Sime, O. Suchowersky, M. Stacy, M. Kurth, M. Brewer, M. Harrigan, D. Russell, B. Fussell, B. Ford, S. Dillon, J. Hammerstad, C. Stone, D. Riley, P. Rainey, D. Standaert, M. Tennis, F. Wooten, E. Rost-ruffner, S. Factor, D. Brown, J. Jankovic, F. Atassi, R. Kurlan, I. Gardiner, M. Panisset, D. Amyot, J. Hall, A. Rajput, T. Shirley, R. Rodnitzky, J. Dobson, C. Shults, D. Fontaine, C. Waters, S. Schuman, R. Pfeiffer, Shirley Rast, B. Pfeiffer, A. Brocht, C. Casaceli, S. Daigneault, K. Hodgeman, K. Honsinger, C. O'Connell, A. Watts (2000)
Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.JAMA, 284 15
C. Patlak, R. Blasberg, J. Fenstermacher (1983)
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake DataJournal of Cerebral Blood Flow & Metabolism, 3
J. Moeller, D. Eidelberg (1997)
Divergent expression of regional metabolic topographies in Parkinson's disease and normal ageing.Brain : a journal of neurology, 120 ( Pt 12)
K. Frey, R. Koeppe, M. Kilbourn (2001)
Imaging the vesicular monoamine transporter.Advances in neurology, 86
D. Brooks (1991)
Detection of preclinical Parkinson's disease with PETNeurology, 41
(2002)
treatment, and pathophysiology
P. Morrish, J. Rakshi, D. Bailey, G. Sawle, D. Brooks (1998)
Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PETJournal of Neurology, Neurosurgery & Psychiatry, 64
Kenneth Marek, R. Innis, C. Dyck, B. Fussell, M. Early, S. Eberly, David Oakes, J. Seibyl (2001)
[123I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progressionNeurology, 57
(2004)
The sensitivity of 18 - fluorodopapositron emission tomography and magnetic resonance imaging in Parkinson ’ s disease
A. Bonnet (2000)
[The Unified Parkinson's Disease Rating Scale].Revue neurologique, 156 5
J. Terwilliger, M. Speer, J. Ott (1993)
Chromosome‐based method for rapid computer simulation in human genetic linkage analysisGenetic Epidemiology, 10
T. Kitada, S. Asakawa, N. Hattori, H. Matsumine, Y. Yamamura, S. Minoshima, M. Yokochi, Y. Mizuno, N. Shimizu (1998)
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonismNature, 392
S. Fahn (1987)
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale, 2
R. Cottingham, R. Idury, A. Schäffer (1993)
Faster sequential genetic linkage computations.American journal of human genetics, 53 1
B. Racette, M. Rundle, J. Wang, A. Goate, N. Saccone, M. Farrer, S. Lincoln, J. Hussey, S. Smemo, J. Lin, B. Suarez, A. Parsian, J. Perlmutter (2002)
A multi-incident, Old-Order Amish family with PDNeurology, 58
P. Morrish, G. Sawle, D. Brooks (1996)
An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.Brain : a journal of neurology, 119 ( Pt 2)
W. Martin, J. Perlmutter (1994)
Assessment of fetal tissue transplantation in Parkinson's diseaseNeurology, 44
U. Wüllner, P. Pakzaban, A. Brownell, P. Hantraye, L. Burns, T. Shoup, D. Elmaleh, A. Petto, R. Spealman, G. Brownell, O. Isacson (1994)
Dopamine Terminal Loss and Onset of Motor Symptoms in MPTP-Treated Monkeys: A Positron Emission Tomography Study with 11C-CFTExperimental Neurology, 126
J. Logan, A. Wolf, C. Shiue, J. Fowler (1987)
Kinetic Modeling of Receptor‐Ligand Binding Applied to Positron Emission Tomographic Studies with Neuroleptic TracersJournal of Neurochemistry, 48
(2001)
Imaging the vesicularmonoamine transporter
(1994)
1994.Assessment of fetal tissue transplantation in Parkinson’s disease: Does PET play a role? Neurology 44:1777–1780
D. Dickson, Matthew Farrer, Sarah Lincoln, R. Mason, T. Zimmerman, L. Golbe, John Hardy (2001)
Pathology of PD in monozygotic twins with a 20-year discordance intervalNeurology, 56
M. Polymeropoulos, C. Lavedan, E. Leroy, S. Ide, A. Dehejia, A. Dutra, B. Pike, H. Root, J. Rubenstein, R. Boyer, E. Stenroos, S. Chandrasekharappa, A. Athanassiadou, T. Papapetropoulos, W. Johnson, A. Lazzarini, R. Duvoisin, G. Iorio, L. Golbe, R. Nussbaum (1997)
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's DiseaseScience, 276
Terence Spinks, T. Jones, Dale Bailey, David Townsend, S. Grootoonk, Peter Bloomfield, M. Gilardi, Michael Casey, B. Sipe, J. Reed (1992)
Physical performance of a positron tomograph for brain imaging with retractable septa.Physics in medicine and biology, 37 8
M. Guttman, V. Yong, Seung Kim, D. Calne, W. Martin, M. Adam, T. Ruth (1988)
Asymptomatic striatal dopamine depletion: PET scans in unilateral MPTP monkeysSynapse, 2
S. Fahn, D. Oakes, I. Shoulson, K. Kieburtz, A. Rudolph, A. Lang, C. Olanow, C. Tanner, K. Marek (2004)
Levodopa and the progression of Parkinson's disease.The New England journal of medicine, 351 24
B. Racette, M. Rundle, A. Parsian, J. Perlmutter (1999)
Evaluation of a screening questionnaire for genetic studies of Parkinson's disease.American journal of medical genetics, 88 5
Parkinson disease (PD) is a late onset disorder with age‐dependent penetrance that may confound genetic studies, since affected individuals may not demonstrate clinical manifestations at the time of evaluation. The use of endophenotypes, biologic surrogates for clinical disease diagnoses, may permit more accurate classification of at‐risk subjects. Positron emission tomography (PET) measurements of 6‐(18F)fluorodopa ((18F)FDOPA) uptake indicate nigrostriatal neuronal integrity and may provide a useful endophenotype for PD linkage studies. We performed (18F)FDOPA PET in 11 members of a large, multi‐incident Amish family with PD, 24 normals and 48 people with clinically definite idiopathic PD (PD controls). Clinical diagnoses in the Amish were clinically definite PD in four, clinically probable in one, clinically possible in five, and normal in one. Abnormal (18F)FDOPA posterior putamen uptake was defined as less than 3 standard deviations below the normal mean. The criteria were applied to the Amish sample to determine a PET endophenotype for each. We performed genetic simulations using SLINK to model the effect phenoconversion with the PET endophenotype had on logarithm of odds (LOD) scores. PET endophenotype confirmed the status of two clinically definite subjects. Two clinically definite Amish PD subjects had normal PETs. Two possible PD were converted to “PET definite PD.” The remainder had normal PETs. The average maximum LOD score with the pre‐PET was 6.14 ± 0.84. Simulating phenoconversion of subjects with unknown phenotypes increased the LOD score to 7.36 ± 1.23. The (18F)FDOPA PET endophenotype permits phenoconversion in multi‐incident PD families and may increase LOD score accuracy and power of an informative pedigree. © 2006 Wiley‐Liss, Inc.
American Journal of Medical Genetics part B – Wiley
Published: Apr 5, 2006
Keywords: Parkinson's disease; positron emission tomography; linkage; endophenotype; Amish
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.